Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21380915 | 0.98 | JAK2 (0.39) | JAK2HPGDDAOHTTLMNA | |
| SCHEMBL21380955 | 0.82 | PDE9A (0.35) | ALDH1A1AKT2CYP1A2MAPK1 | |
| SCHEMBL21380882 | 0.77 | HSD17B10 (0.32) | HPGDALDH1A1CYP1A2 | |
| SCHEMBL21380802 | 0.75 | PTPN11 (0.44) | — | |
| SCHEMBL21380767 | 0.75 | PTPN11 (0.42) | — | |
| SCHEMBL21380875 | 0.75 | PTPN11 (0.37) | — | |
| SCHEMBL21380891 | 0.75 | ENPP1 (0.35) | AKT2 | |
| SCHEMBL21380839 | 0.75 | ENPP1 (0.33) | — | |
| SCHEMBL21380945 | 0.74 | SCN9A (0.34) | HPGDALDH1A1CYP2C9CYP2C19MEN1 | |
| SCHEMBL21380924 | 0.73 | BPTF (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | claimed |
| CN-114502165-A | SHP2 inhibitor and application thereof | 苏州浦合医药科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2021061515-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2021-04-01 | — | — | WO | claimed |
| CN-112368272-A | SHP2 inhibitor and application thereof | 新标立亚医疗有限公司 | 2021-02-12 | — | — | CN | claimed |
| EP-3768664-A1 | SHP2 INHIBITORS AND USES THEREOF | Synblia Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | claimed |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | SYNBLIA THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | claimed |
| WO-2019182960-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | claimed |
| CN-112368272-B | SHP2 inhibitors and uses thereof | 苏州浦合医药科技有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | disclosed |
| CN-114502165-A | SHP2 inhibitor and application thereof | 苏州浦合医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021061515-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| CN-112368272-A | SHP2 inhibitor and application thereof | 新标立亚医疗有限公司 | 2021-02-12 | — | — | CN | disclosed |
| EP-3768664-A1 | SHP2 INHIBITORS AND USES THEREOF | Synblia Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | SYNBLIA THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2019182960-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | JAK2 49/4885HPGD 2665/4885DAO 4019/4885 |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | JAK2 49/4885HPGD 2665/4885DAO 4019/4885 |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | PTPN1, PTPN7, PTPN18 | JAK2 49/4885HPGD 2665/4885DAO 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.